Become a Founding Member for $999 a year, locked for life

    Claim a seat
    MavenlyMavenly

    § Federal grant opportunity · RFA-NS-26-030

    Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

    National Institutes of Health is accepting applications for Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional). The deadline is Rolling / not published and the published award range is Award amount not published.

    Key facts

    Funder
    National Institutes of Health
    Application deadline
    Rolling / not published
    Award range
    Award amount not published
    Eligibility
    nonprofits non higher education with 501c3, special district governments, county governments, other, independent school districts, state governments, for profit organizations other than small businesses, nonprofits non higher education without 501c3, public and indian housing authorities, city or township governments, private institutions of higher education, small businesses, other native american tribal organizations, public and state institutions of higher education, federally recognized native american tribal governments
    Geography
    United States
    Focus areas
    Health
    Opportunity number
    RFA-NS-26-030

    Program overview

    The National Institutes of Neurological Disorders and Stroke (NINDS) is interested in supporting research projects proposing the optimization and translational development of genomic and biologic therapeutic candidates for Alzheimer’s Disease-Related Dementias (ADRD). Breakthroughs in genomic and biologic therapies are creating new opportunities to treat, prevent, and potentially modify the course of dementias; however, progress is limited by challenges in delivery, safety, manufacturability, and readiness for clinical testing. This program is intended to support projects across the translational pipeline, from optimization through IND development and early clinical evaluation, for genomic and biologic therapeutic candidates with compelling preclinical evidence. Eligible projects may include activities to refine therapeutic design and manufacturability; establish pharmacology, toxicology, biodistribution, and in vivo efficacy; to generate the full body of data required to support regulatory interactions and IND submissions, and, when appropriate, first-in-human (FIH) clinical studies. The program is aligned with priorities from the ADRD Summits, including acceleration of disease-modifying therapeutic development in frontotemporal degeneration (FTD), Lewy body dementia (LBD), and vascular contributions to cognitive impairment and dementia (VCID). Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

    How to apply

    1. Confirm your organization meets the eligibility criteria above.
    2. Read the full funding opportunity announcement from National Institutes of Health.
    3. Draft your narrative against the funder's stated priorities and review criteria.
    4. Submit before Rolling / not published, allowing time for registration and validation.

    View the official funding announcement

    Find every grant your organization qualifies for

    Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.